Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TLX

Telix Pharmaceuticals Ltd. ADR

Feb 06 • 04:00PM ET

7.10

+0.14 2.01 %

Healthcare • Biotechnology • Australia • NASD

Peers: LLY MRK JNJ PFE BMY AMGN REGN VRTX BMRN BIIB

Scroll to Statements

Index	-	P/E	229.77	EPS (ttm)	0.03	Insider Own	-	Shs Outstand	334.13M	Perf Week	-2.47%
Market Cap	2.41B	Forward P/E	102.06	EPS next Y	0.07	Insider Trans	-	Shs Float	-	Perf Month	-5.33%
Enterprise Value	2.62B	PEG	5.00	EPS next Q	0.04	Inst Own	0.25%	Short Float	-	Perf Quarter	-31.00%
Income	11.10M	P/S	3.60	EPS this Y	-94.69%	Inst Trans	1.00%	Short Ratio	1.13	Perf Half Y	-39.73%
Sales	667.61M	P/B	5.69	EPS next Y	1320.96%	ROA	1.32%	Short Interest	0.18M	Perf YTD	-5.21%
Book/sh	1.25	P/C	11.61	EPS next 5Y	20.42%	ROE	3.21%	52W High	30.36 -76.61%	Perf Year	-61.49%
Cash/sh	0.61	P/FCF	-	EPS past 3/5Y	- -	ROIC	1.36%	52W Low	6.87 3.35%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	61.10	Sales past 3/5Y	349.15% 192.28%	Gross Margin	58.16%	Volatility	2.92% 2.99%	Perf 5Y	-
Dividend TTM	-	EV/Sales	3.92	EPS Y/Y TTM	-66.43%	Oper. Margin	4.55%	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.22	Sales Y/Y TTM	57.70%	Profit Margin	1.66%	RSI (14)	39.62	Recom	1.13
Dividend Gr. 3/5Y	- -	Current Ratio	1.33	EPS Q/Q	-	SMA20	-5.67%	Beta	0.56	Target Price	16.91
Payout	0.00%	Debt/Eq	0.99	Sales Q/Q	-	SMA50	-13.34%	Rel Volume	1.15	Prev Close	6.96
Employees	-	LT Debt/Eq	0.94	Earnings	Feb 20 BMO	SMA200	-40.57%	Avg Volume	155.75K	Price	7.10
IPO	Nov 14, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-105.10% -0.03%	Trades		Volume	178,715	Change	2.01%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Initiated	Citigroup	Buy	$22
Aug-28-25	Downgrade	JP Morgan	Overweight → Neutral
Jul-03-25	Initiated	H.C. Wainwright	Buy	$23
Jun-05-25	Initiated	Wedbush	Outperform	$22
Nov-15-24	Initiated	UBS	Buy	$21

Feb-03-26 04:35PM	Telix Full Year Results 2025 Investor Webcast Notification (GlobeNewswire)
Jan-21-26 02:15PM	Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure (Benzinga) -5.43%
Jan-20-26 07:00AM	Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch (GlobeNewswire)
Jan-16-26 02:19PM	First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study (GlobeNewswire)
Jan-09-26 03:16AM	Here's What Analysts Think About Telix Pharmaceuticals (TLX) (Insider Monkey)
06:00AM	Loading…
Jan-08-26 06:00AM	Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-26 09:00AM	Telix Pharmaceuticals Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
Dec-29-25 02:41AM	Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TLX (PR Newswire)
Dec-21-25 04:38PM	Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions (GlobeNewswire)
Dec-18-25 05:23AM	Telix Pharmaceuticals Limited (TLX)'s Commercial Progress Meets a Cautious Outlook (Insider Monkey)
Dec-16-25 03:30PM	Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Dec-15-25 12:34PM	Telix Pharma (TLX) Makes Progress With New Study (Insider Monkey)
Dec-10-25 07:00AM	Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration (GlobeNewswire)
Dec-08-25 04:01PM	Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Dec-05-25 03:30PM	Telix Pharmaceuticals Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
07:06PM	Loading…
Dec-01-25 07:06PM	Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Nov-28-25 05:25PM	Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman (PR Newswire)
Nov-25-25 08:03PM	Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman (PR Newswire) +5.13%
08:45AM	Investors in Telix Pharmaceuticals Ltd. Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
Nov-19-25 02:00PM	ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses (GlobeNewswire)
Nov-18-25 03:03PM	Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TLX (PR Newswire)
Nov-13-25 08:25AM	Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Nov-11-25 05:36PM	Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights TLX (Business Wire)
Nov-05-25 06:00AM	Telix to Participate in UBS and Jefferies Global Healthcare Conferences (GlobeNewswire)
Oct-23-25 07:00AM	TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging (GlobeNewswire)
Oct-22-25 04:00PM	Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain (GlobeNewswire)
Oct-14-25 02:22AM	Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded (GlobeNewswire) +5.24%
Sep-30-25 04:12AM	Telix Pharmaceuticals (TLX) Limited Receives Transitional Pass-Through payment status for Gozellix (Insider Monkey)
Sep-23-25 10:15AM	CMS Grants Transitional Pass-Through Status for Gozellix (GlobeNewswire) +8.76%
Sep-18-25 10:40AM	Telix Pharmaceuticals Limited (TLX) Increases R&D by 47%, Progresses Key Prostate and Brain Cancer Trials (Insider Monkey)
09:47AM	Loading…
Sep-16-25 09:47AM	Telix Pharmaceuticals Begins Phase 3 Trial for Prostate Cancer Diagnostics (Insider Monkey)
Sep-09-25 07:00PM	Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis (GlobeNewswire)
Aug-26-25 07:00AM	Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-20-25 08:22PM	Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth (GlobeNewswire) +10.21%
05:23AM	Target, Lowe's and TJX earnings to give update on consumer spending (MarketWatch)
04:36AM	Stock Market Today: Nasdaq futures lead Dow and S&P 500 lower as rotation out of big tech continues; Target earnings on tap; traders await Powell's Friday speech. (MarketWatch)
Jul-29-25 06:58PM	Telix H1 2025 Results: Investor Webcast Notification (GlobeNewswire)
Jul-22-25 04:39AM	Telix Pharma Q2 Revenue Up 63%; Confirms FY25 Revenue Guidance (RTT News)
04:06AM	Telix Reports $204M Revenue, Up 63% YOY (GlobeNewswire)
Jul-09-25 06:45PM	Gozellix Receives Permanent HCPCS Code (GlobeNewswire) +7.84%
Jul-03-25 09:41AM	Meta upgraded, PNC Financial downgraded: Wall Street's top analyst calls (The Fly)
Jun-29-25 01:28PM	Telix Pharmaceuticals (TLX) Announces That US FDA Approves Label Expansion for Illuccix (Insider Monkey)
Jun-25-25 04:04AM	Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses (PR Newswire)
Jun-23-25 07:15AM	Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT (GlobeNewswire)
Jun-20-25 08:00AM	Telix Precision Medicine Announces AlFluor Radiochemistry Platform (GlobeNewswire)
Jun-19-25 08:18PM	Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025 (GlobeNewswire)
Jun-13-25 04:35AM	Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Greece (PR Newswire) -7.85%
Jun-11-25 07:00AM	Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S. (GlobeNewswire)
Jun-05-25 02:15AM	Telix's Illuccix PSMA-PET Imaging Agent Approved in Germany (PR Newswire)
Jun-04-25 12:55AM	Telix's Illuccix PSMA-PET Imaging Agent Approved in Portugal (PR Newswire)
Jun-03-25 06:30PM	Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan (PR Newswire)
06:57AM	Telix Investor Day in New York City on June 11, 2025: Presenting KOLs (GlobeNewswire)
May-22-25 08:00AM	Telix to Host Investor Day in New York City on June 11, 2025 (GlobeNewswire)
May-19-25 06:00PM	Telix at ANZSNM Annual Scientific Meeting 2025 (PR Newswire)
May-12-25 07:22PM	Illuccix China Phase 3 Study Completes Enrolment (PR Newswire) -5.41%
May-07-25 04:13PM	Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy (GlobeNewswire)
May-05-25 04:55AM	Telix's Illuccix PSMA-PET Imaging Agent Approved in the Czech Republic (PR Newswire)
Apr-30-25 02:17AM	Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland (PR Newswire)
Apr-28-25 06:30PM	Telix's Illuccix PSMA-PET Imaging Agent Approved in France (GlobeNewswire) -6.54%
Apr-22-25 04:17AM	Telix Reports US$186M Q1 Revenue, Up 62% YOY (GlobeNewswire)
Apr-15-25 07:04PM	IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate (PR Newswire)
02:16AM	Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden (PR Newswire)
Apr-14-25 12:00PM	All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy (Zacks)
Apr-09-25 01:30PM	Telix Shares May Gain on the Distribution Deal With Cardinal Health (Zacks) +11.18%
Apr-08-25 06:30AM	Telix Announces Cardinal Health for Gozellix Commercial Distribution (GlobeNewswire)
Apr-07-25 06:30AM	Telix Appoints Paul Schaffer as Chief Technology Officer (GlobeNewswire)
Apr-06-25 07:09PM	Telix Appoints Paul Schaffer as Chief Technology Officer (PR Newswire)
Apr-05-25 01:03AM	Telix Pharmaceuticals: Building A Radiopharma Powerhouse (Seeking Alpha)
Apr-03-25 06:13PM	Anne Whitaker Appointed as Non-Executive Director (GlobeNewswire) -15.73%
Apr-01-25 03:30PM	Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma (GlobeNewswire)
08:49AM	ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix (GlobeNewswire)
Mar-23-25 12:00PM	Lantheus Holdings: One Blockbuster, Evolving Pipeline (SeekingAlpha)
Mar-21-25 10:40AM	Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent (Investopedia)
06:30AM	FDA Approves New Prostate Cancer Imaging Agent Gozellix (GlobeNewswire)
Mar-20-25 08:38PM	FDA Approves New Prostate Cancer Imaging Agent Gozellix® (PR Newswire)
Mar-17-25 07:37PM	Illuccix Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America (PR Newswire)
Mar-12-25 07:11PM	Telix Adds Lead-212 Isotope Production Capability (PR Newswire)
Mar-03-25 04:48PM	Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum (GlobeNewswire)
Feb-25-25 08:01PM	FDA Accepts BLA for TLX250-CDx (Zircaix) for Kidney Cancer Imaging, Grants Priority Review (PR Newswire) -6.83%
07:30AM	Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami (GlobeNewswire)
04:48AM	Illuccix Prostate Cancer Imaging Agent Approved in Luxembourg (PR Newswire)
Feb-24-25 12:00PM	Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.33%
01:00AM	Telix's Illuccix PSMA-PET Imaging Agent Approved in Norway (PR Newswire)
Feb-20-25 07:35AM	Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion (PR Newswire)
Feb-13-25 07:00AM	Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025) (GlobeNewswire)
Feb-12-25 04:38PM	Illuccix Approved in the United Kingdom (GlobeNewswire)
Feb-11-25 05:22AM	Illuccix Approved in Denmark (PR Newswire)
Jan-30-25 04:57PM	Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform (GlobeNewswire)
Jan-27-25 04:43PM	Telix Completes Acquisition of RLS (USA) Inc. (GlobeNewswire)
Jan-22-25 01:05PM	ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery (PR Newswire)
Jan-16-25 05:24PM	Illuccix Receives European Approval (PR Newswire)
Jan-13-25 04:35PM	Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.60%
02:08AM	Telix Exceeds FY24 Guidance with US$142M Q4 Revenue (GlobeNewswire)
12:11AM	Scintimun Commercialization Partnership with Curium Pharma (PR Newswire)
Jan-12-25 05:04PM	Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform (GlobeNewswire)
Dec-30-24 03:45PM	NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports (PR Newswire)
Dec-29-24 04:53PM	Telix Files TLX250-CDx (Zircaix ) BLA for Kidney Cancer Imaging (GlobeNewswire)
Dec-19-24 07:00AM	Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete (GlobeNewswire)
Nov-28-24 04:22AM	First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients (PR Newswire)
Nov-18-24 06:20PM	Telix to Add FAP-Targeting Candidates to Theranostic Pipeline (GlobeNewswire)

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLX

Telix Pharmaceuticals Ltd. ADR

Upgrade your FINVIZ experience